Drinking-water medication in grower-finisher swine units

In farrow-to-finish and multi-site grower-finisher operations, doxycycline hyclate water-soluble powder is metered into drinking lines for treatment of porcine respiratory disease complex associated with Mycoplasma hyopneumoniae and Pasteurella multocida. The most consequential production-floor variable is not the API assay but the measured 24 h water intake, because the target dose of 10–20 mg/kg bodyweight/day must be converted into a running concentration in drinking water. A 50% w/w water-soluble powder is commonly introduced at 0.2–0.5 g product/L, yielding 0.10–0.25 g/L doxycycline hyclate when pigs consume 80–120 mL/kg/day; this range is adjusted after rechecking the previous 24 h intake at the drinker line, not from historical batch records. Water quality is a hard constraint: doxycycline hyclate chelates calcium and magnesium, and hard water above 250 mg/L CaCO₃ produces precipitation, blocked nipple drinkers, and variable ingestion. Soluble powder formulations therefore include anhydrous citric acid to depress reconstituted water pH to 4.5–5.5, and supply-chain control limits total divalent cation concentration to <50 mg/L in the target water matrix. The dry blend is manufactured in a 500 L ploughshare mixer at 25 rpm for 15 min after the API is pre-sieved through a 500 µm screen; excipients are dried to moisture <2.0%. Blend uniformity is tested from 10 points with an acceptance range of 90–110% label claim, and the powder is packed into aluminium/PET/PE laminate sachets at relative humidity <35%. Compliance anchors are Regulation (EU) 2019/6 for veterinary medicinal products, the Ph. Eur. monograph for doxycycline hyclate, VICH GL18 for residual solvents, and ICH Q3D(R2) for elemental impurities. Terminal finished product types are 100 g, 500 g, and 1 kg sachets of water-soluble powder for oral solution. Reconstituted solutions are held for no more than 24 h and protected from light; simultaneous administration through calcium-fortified water lines is avoided because insoluble doxycycline-calcium complexes reduce systemic exposure and block drinker valves.

Broiler water-line flow rate is the controlling variable when doxycycline hyclate water-soluble granules are used against Mycoplasma gallisepticum and Escherichia coli secondary airsacculitis, because nipple drinker hydraulic capacity and house temperature drive water intake in a range of 100–150 mL/kg/day. To achieve 10–25 mg/kg bodyweight/day over 3–5 days, a 50% w/w granule is diluted at 0.20–0.40 g product/L, corresponding to 0.10–0.20 g/L doxycycline hyclate; the higher concentration is used only after a measured intake shortfall, not as a routine. The production route for granules differs from simple powder blending because a dry granulation roller compactor is used at roll pressure 8–15 kN/cm to bind doxycycline hyclate with anhydrous lactose and polyvinylpyrrolidone without introducing aqueous binder, which would accelerate hydrolysis to 6-epidoxycycline. Granules are milled to a particle-size distribution 150–850 µm with fines <15%, then filled into 1 kg HDPE bottles with induction-sealed liners under nitrogen flush to limit oxidative yellowing. Finished product types are 50% w/w water-soluble granules for oral use in broilers and turkeys. Compliance is established by Regulation (EU) 2019/6, Ph. Eur. 2.9.5 uniformity of mass of single-dose preparations, and ICH Q3D(R2) for elemental impurities. The granule formulation must also include a citric acid buffer to maintain reconstituted solution pH 4.0–5.0 because alkaline or high-calcium water precipitates doxycycline and reduces bioavailability; in-line monitoring of pH at the start of each drinker line is required wherever source water exceeds 120 mg/L CaCO₃ hardness.

Can doxycycline hyclate be terminally sterilized in anhydrous injectable vehicles?

No terminal sterilization cycle is suitable for doxycycline hyclate injectable formulations at concentrations of 100–200 mg/mL doxycycline base, because the molecule undergoes rapid C4 epimerization and oxidative discoloration above 60°C, and autoclaving at 121°C increases 6-epidoxycycline and anhydrodoxycycline beyond Ph. Eur. related-substances limits. The manufacturing line therefore uses a low-water or anhydrous vehicle based on propylene glycol, ethanol, and water at an acidic pH of 3.0–4.5, with an antioxidant and a chelating agent included to control dissolved metal ions. The API charge is corrected by the salt factor 1.15 from doxycycline base to doxycycline hyclate and further adjusted for potency and water content; a 200 mg/mL base label claim requires 230 mg/mL doxycycline hyclate before assay correction. Production occurs in a vessel purged with nitrogen, with the pre-dried API dispersed at 500–800 rpm below 25°C, followed by sterile filtration through a 0.22 µm PVDF filter. Filter adsorption must be validated because doxycycline can bind to nylon and some polyethersulfone membranes; filter discard volume and product hold time are controlled to <12 h before filling. The filtered solution is filled into amber Type II glass vials under Grade A aseptic conditions according to EU GMP Annex 1 (2022), with nitrogen overlay and bromobutyl rubber stoppers. Sterility testing follows Ph. Eur. 5.1.1, bacterial endotoxins Ph. Eur. 2.6.14, and subvisible particulates USP 787. Terminal product types are 100 mg/mL and 200 mg/mL solutions for parenteral administration in 50 mL, 100 mL, and 250 mL vials for cattle and swine. Operational limitations include no contact with aluminium filling parts due to pH-driven ion release, and no terminal sterilisation; lines that routinely autoclave other veterinary injectables must segregate doxycycline batches to avoid thermal damage. Published data for the optimal antioxidant system in high-concentration doxycycline injection is limited, so forced-degradation comparison against an untreated control is required before the first commercial batch is released.

Direct-compression and dry-granulation lines for companion animal tablets face a different set of restrictions: doxycycline hyclate is hygroscopic, light-sensitive, and incompatible with calcium phosphate diluents that are otherwise standard in veterinary tableting. Tablets for dogs and cats are labelled in doxycycline base equivalents, so a 100 mg base tablet uses 115 mg doxycycline hyclate per unit before the factor 1.15 and assay correction. Formula API salt content typically ranges from 25–65% w/w depending on dose and tablet weight; low-dose 20 mg tablets are geometrically diluted with anhydrous lactose and microcrystalline cellulose, while higher-dose 100 mg tablets use roller compaction at 8–12 kN/cm to produce granules of 200–600 µm. The granulation is lubricated with 0.5–1.0% w/w magnesium stearate and compressed to hardness 60–100 N on a rotary press at 10–20 rpm turret speed. Dicalcium phosphate is excluded from the diluent system because calcium ions chelate the phenolic-diketone moiety and reduce dissolution; crospovidone and sodium starch glycolate are used as disintegrants instead. Film coating with an HPMC/PEG system is applied to a 2.5–4.0% w/w weight gain to reduce photodegradation and mask the bitter taste. Dissolution testing follows USP 711 with apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl; uniformity of dosage units follows USP 905. Compliance is under FDA 21 CFR Part 211 for finished veterinary tablets and the USP Doxycycline Hyclate Tablets monograph. Terminal finished product types are 20 mg, 50 mg, and 100 mg tablets and 50 mg and 100 mg capsules for dogs, cats, and horses. Batches are quarantined if water activity exceeds 0.3 before compression because increased free moisture accelerates 6-epidoxycycline formation during storage and shifts the dissolution profile beyond the monograph Q-value.

When a 10% w/w medicated feed premix is applied through post-pellet fat spraying

Medicated feed premix manufacture for swine uses doxycycline hyclate as a 5% w/w or 10% w/w granular premix diluted into final feed at 1–4 kg/t. For a 5% w/w premix, 2–4 kg/t final feed provides 100–200 ppm doxycycline base; for a 10% w/w premix, 1–2 kg/t delivers the same 100–200 ppm range. The dose is calculated from a 10–20 mg/kg bodyweight/day target and a feed intake of 5% bodyweight/day, but the line must not apply these values without rechecking actual feed consumption on site. The premix is produced by blending the API with wheat middlings or lactose carrier and 0.5–1.0% w/w mineral oil binder in a ribbon mixer, followed by dry granulation to reduce dust and prevent segregation in bulk feed transport. Granulation via a roller compactor at 10–14 kN/cm yields particles of 200–800 µm; this size range aligns with the particle distribution of feed and improves band uniformity in auger dosing systems. The most critical process boundary is heat: doxycycline hyclate premix must be added after pelleting or through post-pellet fat spray lines because pellet die temperatures above 70°C accelerate loss of potency and increase related substances; where compound feed is pelleted at 80–95°C, the premix is metered into cooled, post-pellet coated feed rather than into the pre-conditioner. Homogeneity is verified according to EU Regulation 2019/4 on medicated feed, with 10 sample points and a target coefficient of variation below 5%; carryover limits are managed through flush batches and sequencing of non-medicated feed. Compliance standards are EU Regulation 2019/4, European Pharmacopoeia, ICH Q7 for API GMP, and VICH GL10 for impurity control in veterinary drug substances. Terminal products are 25 kg paper/PE sacks of 5% w/w and 10% w/w doxycycline premix granules, ultimately incorporated into meal or pelleted medicated feed for grower-finisher pigs. The final feed is used only under a veterinary prescription and carries a withdrawal period determined by the registered premix; no single API-derived withdrawal period may be printed on export documentation as universally applicable.

Oral solution formulation for equine foals and selected zoo species is constrained less by manufacturing throughput than by the hydrolytic instability of doxycycline hyclate in aqueous media above pH 5.0. A liquid product labelled at 10 mg/mL doxycycline base is prepared from 11.5 mg/mL doxycycline hyclate in a vehicle of purified water, glycerin, citric acid buffer, and a light-protective amber packaging system. The solution pH is maintained at 4.0–5.0 to minimize epimerization and to keep the weakly basic API dissolved; pH above 5.5 causes precipitation of the less soluble base form, while pH below 3.0 accelerates degradation to anhydrodoxycycline. Production uses a low-shear planetary mixer to disperse the API in glycerin before the aqueous phase is added, reducing local pH excursion and foaming; the solution is then passed through a 100 µm strainer and filled into 100 mL and 250 mL amber polyethylene terephthalate bottles with child-resistant closures. The batch is sparged with nitrogen during compounding and the bottle headspace is flushed with nitrogen before induction sealing. Compliance is anchored to Regulation (EU) 2019/6, Ph. Eur. 2.9.5 for uniformity of mass, and ICH Q3C(R8) for residual solvents; if prepared extemporaneously, USP 795 specifications for nonsterile compounding apply. Terminal finished product types are 10 mg/mL oral solution for equine foals and 20 mg/mL oral solution for swine and calves, in 100 mL, 250 mL, and 1 L bottles. The operational boundary is a refrigerated shelf life of 14 days once the primary bottle is opened, due to oxygen ingress and photodegradation; continuous light exposure or storage above 25°C produces visible yellowing and an increase in 6-epidoxycycline beyond the Ph. Eur. related-substances threshold.